免疫治疗下新型缓解模式
本文综述了免疫治疗中出现的非常规缓解与进展模式,包括持久缓解、假性进展、超进展和分离缓解。假性进展报告率不超过10%,超进展报告率为4%至29%。多种免疫特异性缓解标准仅涵盖假性进展,经典RECIST仍是临床评估的合理方法。
要点
- 持久缓解无统一定义,最佳治疗时长未明确。
- 假性进展报告率不超过10%,超进展报告率为4%至29%。
- 免疫特异性缓解标准仅涵盖假性进展,未涵盖超进展与分离缓解。
核心结论
- 免疫治疗可出现持久缓解、假性进展、超进展和分离缓解等非常规模式;经典RECIST仍是临床评估免疫治疗缓解的合理且有意义的方法。
研究设计与样本
- 综述,总结免疫治疗下新型缓解与进展模式的文献报道。
主要发现
- 持久缓解可在部分晚期癌症患者中维持数年,甚至停药后仍可维持。
- 假性进展最初在晚期黑色素瘤患者中报告,表现为初始进展后肿瘤指标病灶退缩;报告率不超过10%。
- 超进展报告率为4%至29%,这些观察需随机试验证实。
- 部分患者出现分离缓解,即部分病灶缩小而另一些病灶增大。
关键数值与推荐
- 持久缓解在文献中无标准化定义,持久缓解时的最佳治疗时长未明确建立。
- 假性进展报告率不超过10%。
- 超进展报告率为4%至29%。
临床怎么用
- 仅应在仔细选择、有临床获益且未发生严重免疫治疗毒性的患者中决定进展后继续治疗。
- 超进展患者必须中断治疗,以换用另一种可能有效的治疗。
- 对增大的病灶可考虑局部手术或放疗。
- 经典RECIST仍是临床上评估免疫治疗缓解的合理且有意义的方法。
局限性
- 持久缓解在文献中无标准化定义,持久缓解时的最佳治疗时长未明确建立。
- 超进展的观察需随机试验证实。
- 免疫特异性缓解标准仅涵盖假性进展模式,未涵盖超进展和分离缓解等其他模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10%, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4% to 29%. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
引用
- Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019. PMID: 30657859. doi:10.1093/annonc/mdz003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。